Angiogenesis and Cancer

January 24-28, 1998
Hyatt Orlando
Orlando, FL

CONFERENCE CO-CHAIRPERSONS

Judah Folkman / Boston, MA
Michael Klagsbrun / Boston, MA

CONFERENCE PROGRAM

Keynote Address
Nicole Le Douarin / Nogent sur Marne, France

Blood Vessels and Development
Patricia D'Amore / Boston, MA
Donald E. Ingber / Boston, MA
Jeffrey M. Isner / Boston, MA

Mechanisms of Vasculogenesis and Angiogenesis
Werner Risau / Bad Nauheim, Germany
Peter Carmeliet / Leuven, Belgium
Douglas Hanahan / San Francisco, CA

VEGF and VEGF Receptors
Kari K. Alitalo / Helsinki, Finland
Harold F. Dvorak / Boston, MA
Napoleone Ferrara / S. San Francisco, CA
Kenneth A. Thomas / West Point, PA

Angiopoietin and TIE Receptors
George D. Yancopoulos / Tarrytown, NY
Bjorn R. Olsen / Boston, MA

Tumor Angiogenesis and Metastasis
Rakesh K. Jain / Boston, MA
Robert S. Kerbel / Toronto, Ontario, Canada
Isaiah J. Fidler / Houston, TX
Ann F. Chambers / London, Ontario, Canada

Inhibitors of Angiogenesis
Luisa Iruela-Arispe / Boston, MA
Noël Bouck / Chicago, IL
David A. Cheresh / La Jolla, CA

Clinical Applications
Noel Weidner / San Francisco, CA
Judah Folkman / Boston, MA

Additional Speakers to be Announced

Application Deadline: October 13, 1997

Information and Application Forms:
American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
E-mail: aacr@aacr.org
Website: http://www.aacr.org
Transcriptional Control of Proliferation, Differentiation, and Development

October 17-21, 1997
The Sagamore, Bolton Landing (Lake George), New York

CONFERENCE CHAIRPERSONS
Robert N. Eisenman / Seattle, WA
Elaine V. Fuchs / Chicago, IL

SCIENTIFIC PROGRAM

Keynote Session
Michael G. Rosenfeld / San Diego, CA
Stephen K. Burley / New York, NY
Michael R. Green / Worcester, MA

Transcriptional Mechanisms
Richard A. Young / Cambridge, MA
Joan W. Conaway / Oklahoma City, OK
James L. Manley / New York, NY
Cynthia Wolberger / Baltimore, MD

The Influence of Chromatin Structure on Transcription
Beverly M. Emerson / La Jolla, CA
Alan P. Wolff / Bethesda, MD

Transcriptional Regulation of the Cell Cycle
David M. Livingston / Boston, MA
Bruce A. Edgar / Seattle, WA
Charles J. Sherr / Memphis, TN
Erin K. O'Shea / San Francisco, CA

Signal Transduction and Transcription
Gerald R. Crabtree / Stanford, CA
Joan Massague / New York, NY
Hans C. Clevers / Utrecht, The Netherlands

Oncogenic and Anti-Oncogenic Transcription Factors
Carol Prives / New York, NY
A. Thomas Look / Memphis, TN
George F. Vande Woude / Frederick, MD
Robert N. Eisenman / Seattle, WA

Transcription Control of Differentiation
David Baltimore / Cambridge, MA
Bruce M. Spiegelman / Boston, MA
Elaine V. Fuchs / Chicago, IL

Gene Manipulating Strategies
Robb Krumlauf / London, England
Spyros Artavanis-Tsakonas / New Haven, CT
Eric N. Olson / Dallas, TX
Norbert Perrimon / Boston, MA

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
E-mail: aacr@aacr.org
In 1945, the Southeastern Michigan Chapter of the American Cancer Society (ACS) and the community raised $250,000 to purchase a building, which then became the DICR after remodeling under the direction of Harvey Marker of Parke-Davis. William L. Simpson was appointed Director in 1947. Title to the headquarters and laboratories was turned over to the newly created MCF in 1947 when the ACS decreed that none of its chapters could own property or operate clinics or laboratories. With further remodeling, these laboratories housed cancer studies for some 25 years.

During this period, Jerome P. Horwitz synthesized azidothymidine (AZT) in the DICR Chemistry Laboratory. Designed as an antitumor drug, it would become the first AIDS drug approved by the FDA two decades later. Two other AIDS drugs (ddC and d4t) were created by Dr. Horwitz in the late 1960s. In 1966, the DICR, the Yates Cancer Detection Clinic, and the Michigan Cancer Registry merged into the MCF. At this time, Michael J. Brennan, Chief of Medical Oncology at Henry Ford Hospital, was appointed President of the enlarged organization. In 1973, the MCF opened its new 120,000 square foot headquarters and laboratories (right) named after Meyer L. Prentis, the first Treasurer of the General Motors Corporation.

One of the initial accomplishments of the MCF was the establishment of the first hormone-dependent human breast cancer cell line, MCF-7, by Dr. Soule as described above. At this time, the cancer registry maintained by the MCF was invited to join the NCI’s SEER Program. Within a short period, WSU and the MCF created the Cancer Center of Metropolitan Detroit, which soon was designated a comprehensive cancer center by the National Cancer Institute (1978). This Center, which coordinated the efforts of over 100 investigators and clinicians, was initially directed by Dr. Brennan and later by Laurence Baker, who was appointed Director in 1988. Maintaining his devotion to research and breast cell culture, Dr. Soule culminated 5 years of effort in 1989 by developing the MCF-10 cell line, an immortalized nonmalignant human breast epithelial line. These cells, which had not been exposed to viruses or carcinogens, have become a valuable model for the study of breast cell transformation.

During this period, the experimental therapeutics group of the MCF discovered the anticancer activity of pyrazoloacridine (PZA) for use against solid tumors. Presently this agent is in national clinical trials.

Dr. Brennan retired in 1991 and was replaced as President by Vainutis Vaitkevicius, who brought about the merger of the MCF, the Meyer L. Prentis Comprehensive Cancer Center of Metropolitan Detroit, and the cancer programs of WSU and the Detroit Medical Center, creating one of the country’s largest centers dedicated to cancer research and treatment. The merger was followed by the completion of the Wertz Clinical Cancer Center (bottom left), which provides outpatient chemotherapy and houses multidisciplinary clinics and patient education programs.

After the retirement of Dr. Vaitkevicius, William Peters was recruited to head the newly combined center, which received a $15 million gift from Peter Karmanos, Jr., to honor his late wife Barbara. As President and Chief Executive Officer of the Barbara Ann Karmanos Cancer Institute, Director of the Meyer L. Prentis Comprehensive Cancer Center at Metropolitan Detroit, and Associate Dean for Cancer Programs within WSU, Dr. Peters directs an organization with an operating budget of $170 million, including $27 million in grants and contracts, which supports the investigations of 140 scientists and clinicians and 61,000 patient encounters annually. The Karmanos Cancer Institute preserves the legacies of Dr. Soule, patient tissue donors, and the MCF by continuing to provide cell lines for research to investigators worldwide through its Cell Lines Resource.

We are grateful to Sam C. Brooks, Professor of Biochemistry and Molecular Biology, WSU School of Medicine, and Robert J. Pauley, Associate Professor, Karmanos Cancer Institute, for their assistance in coordinating the material for this cover feature.

Sidney Weinhouse